Summit Therapeutics PLC宣布，美国食品药品监督管理局（FDA）已正式受理其提交的生物制品许可申请（BLA）。该申请旨在寻求批准Ivonescimab与化疗联合，用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者，这些患者此前已接受过酪氨酸激酶抑制剂（TKI）治疗。
Summit Therapeutics PLC宣布，美国食品药品监督管理局（FDA）已正式受理其提交的生物制品许可申请（BLA）。该申请旨在寻求批准Ivonescimab与化疗联合，用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者，这些患者此前已接受过酪氨酸激酶抑制剂（TKI）治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.